Mikaela Naylon Give Kids a Chance Act
Official title: To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
More subjectsShow fewer subjects
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Received in the Senate.
Give Kids a Chance Act of 2025
This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research.
Specifically, the bill
- modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met;
- permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement;
- renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and
- reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research.
The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra, a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)
- Engrossed in House Formatted Text PDF Formatted XML
- Introduced in House Formatted Text PDF Formatted XML
- Reported in House Formatted Text PDF Formatted XML
- NATIONWIDE CHILDREN'S HOSPITAL, INC.
- NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES
- DANA-FARBER CANCER INSTITUTE
- BIOGEN
- MEHLMAN CONSULTING, INC.
- ACADIA PHARMACEUTICALS
Bodies those filers lobbied
- SENATE
- HOUSE OF REPRESENTATIVES
- Health & Human Services, Dept of (HHS)
- Centers For Medicare and Medicaid Services (CMS)
- Food & Drug Administration (FDA)
- White House Office
- Office of Management & Budget (OMB)
- U.S. Trade Representative (USTR)
Cite this page
U.S. Congress. (2026). H.R. 1262: Mikaela Naylon Give Kids a Chance Act. 119th Congress. Open America. https://openamerica.io/bill/119-HR-1262/
"H.R. 1262: Mikaela Naylon Give Kids a Chance Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-1262/.
H.R. 1262, 119th Cong. (2026), https://openamerica.io/bill/119-HR-1262/.
[H.R. 1262: Mikaela Naylon Give Kids a Chance Act](https://openamerica.io/bill/119-HR-1262/)